Clinical Commissioning Policy: Rituximab for Immunobullous Disease

NHS England will commission rituximab for immunobullous diseases, pemphigus and pemphigoid, in adults and children who meet the defined criteria, but there is not enough evidence at present to consider making it available to treat epidermolysis bullosa acquisita.

Source:

NHS England